Yi-Ping Li1, Hye-Na Kang, Lorne-A Babiuk, Qiang Liu. 1. Vaccine and Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan, S7N 5E3, Canada.
Abstract
AIM: To characterize the immunogenicity of a hepatitis C virus (HCV) E2 DNA vaccine alone or with a protein vaccine boost in murine and porcine animal models. METHODS: A DNA vaccine expressing a secreted form of HCV E2 protein was constructed and used to vaccinate mice and piglets with or without boosting with a recombinant E2 protein vaccine formulated with CpG ODN and 10% Emulsigen. The immunogenicity of HCV E2 vaccines was analyzed by ELISA for antibody responses, MTT assay for lymphocyte proliferation, ELISPOT for the number of interferon-gamma secreting cells, and cytotoxic T lymphocyte assays. RESULTS: Intradermal injection of E2 DNA vaccine induced strong Th1-like immune responses in mice. In piglets, E2 DNA vaccine elicited moderate and more balanced immune responses. A DNA vaccine prime and protein boost vaccination strategy induced significantly higher E2-specific antibody levels and shifted the immune response towards Th2-like ones in piglets. CONCLUSION: A DNA vaccine expressing a secreted form of HCV E2 protein elicited E2-specific immune responses in mice and piglets. Recombinant E2 protein vaccination following DNA immunization significantly increased the antibody response in piglets. These HCV E2 vaccines may represent promising hepatitis C vaccine candidates for further investigations.
AIM: To characterize the immunogenicity of a hepatitis C virus (HCV) E2 DNA vaccine alone or with a protein vaccine boost in murine and porcine animal models. METHODS: A DNA vaccine expressing a secreted form of HCV E2 protein was constructed and used to vaccinate mice and piglets with or without boosting with a recombinant E2 protein vaccine formulated with CpG ODN and 10% Emulsigen. The immunogenicity of HCV E2 vaccines was analyzed by ELISA for antibody responses, MTT assay for lymphocyte proliferation, ELISPOT for the number of interferon-gamma secreting cells, and cytotoxic T lymphocyte assays. RESULTS: Intradermal injection of E2 DNA vaccine induced strong Th1-like immune responses in mice. In piglets, E2 DNA vaccine elicited moderate and more balanced immune responses. A DNA vaccine prime and protein boost vaccination strategy induced significantly higher E2-specific antibody levels and shifted the immune response towards Th2-like ones in piglets. CONCLUSION: A DNA vaccine expressing a secreted form of HCV E2 protein elicited E2-specific immune responses in mice and piglets. Recombinant E2 protein vaccination following DNA immunization significantly increased the antibody response in piglets. These HCV E2 vaccines may represent promising hepatitis C vaccine candidates for further investigations.
Authors: C Rollier; E Depla; J A R Drexhage; E J Verschoor; B E Verstrepen; A Fatmi; C Brinster; A Fournillier; J A Whelan; M Whelan; D Jacobs; G Maertens; G Inchauspé; J L Heeney Journal: J Virol Date: 2004-01 Impact factor: 5.103
Authors: X P Ioannou; S M Gomis; B Karvonen; R Hecker; L A Babiuk; S van Drunen Littel-van den Hurk Journal: Vaccine Date: 2002-11-22 Impact factor: 3.641
Authors: B Grubor-Bauk; W Yu; D Wijesundara; J Gummow; T Garrod; A J Brennan; I Voskoboinik; E J Gowans Journal: Gene Ther Date: 2015-10-01 Impact factor: 5.250
Authors: Reem R Al Olaby; Laurence Cocquerel; Adam Zemla; Laure Saas; Jean Dubuisson; Jost Vielmetter; Joseph Marcotrigiano; Abdul Ghafoor Khan; Felipe Vences Catalan; Alexander L Perryman; Joel S Freundlich; Stefano Forli; Shoshana Levy; Rod Balhorn; Hassan M Azzazy Journal: PLoS One Date: 2014-10-30 Impact factor: 3.240
Authors: Abdellatif Bouazzaoui; Ahmed A H Abdellatif; Faisal A Al-Allaf; Neda M Bogari; Saied Al-Dehlawi; Sameer H Qari Journal: Pharmaceutics Date: 2021-01-22 Impact factor: 6.321